Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

1.

MO-AB-207-04: ACR Update in Mammography.

Berns E.

Med Phys. 2015 Jun;42(6):3549. doi: 10.1118/1.4925285.

PMID:
26128581
2.

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG), Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO), Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO), National Cancer Research Institute (NCRI), Australia New Zealand Gynaecological Oncology Group (ANZGOG), and the Mario Negri Gynecologic Oncology group (MaNGO).

Target Oncol. 2015 May 26. [Epub ahead of print]

PMID:
26004768
3.

MicroRNA regulation of RAD51 in serous ovarian cancer modulates chemotherapy response.

Wiemer EA, Berns EM.

J Natl Cancer Inst. 2015 May 20;107(7). pii: djv161. doi: 10.1093/jnci/djv161. Print 2015 Jul. No abstract available.

PMID:
25995443
4.

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.

Kriege M, Jager A, Hollestelle A, Berns EM, Blom J, Meijer-van Gelder ME, Sieuwerts AM, van den Ouweland A, Collée JM, Kroep JR, Martens JW, Hooning MJ, Seynaeve C.

J Cancer Res Clin Oncol. 2015 May 10. [Epub ahead of print]

PMID:
25958056
5.

Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.

Jansen MP, Sas L, Sieuwerts AM, Van Cauwenberghe C, Ramirez-Ardila D, Look M, Ruigrok-Ritstier K, Finetti P, Bertucci F, Timmermans MM, van Deurzen CH, Martens JW, Simon I, Roepman P, Linn SC, van Dam P, Kok M, Lardon F, Vermeulen PB, Foekens JA, Dirix L, Berns EM, Van Laere S.

Mol Oncol. 2015 Jun;9(6):1218-33. doi: 10.1016/j.molonc.2015.02.006. Epub 2015 Mar 4.

PMID:
25771305
6.

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, van IJcken WF, Heine AA, Smid M, Koudijs MJ, Brenton JD, Berns EM, Helleman J.

PLoS One. 2014 Sep 17;9(9):e103988. doi: 10.1371/journal.pone.0103988. eCollection 2014.

7.

β1-Integrin and integrin linked kinase regulate astrocytic differentiation of neural stem cells.

Pan L, North HA, Sahni V, Jeong SJ, Mcguire TL, Berns EJ, Stupp SI, Kessler JA.

PLoS One. 2014 Aug 6;9(8):e104335. doi: 10.1371/journal.pone.0104335. eCollection 2014.

8.

A bioengineered peripheral nerve construct using aligned peptide amphiphile nanofibers.

Li A, Hokugo A, Yalom A, Berns EJ, Stephanopoulos N, McClendon MT, Segovia LA, Spigelman I, Stupp SI, Jarrahy R.

Biomaterials. 2014 Oct;35(31):8780-90. doi: 10.1016/j.biomaterials.2014.06.049. Epub 2014 Jul 23.

PMID:
25064803
9.

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.

Kriege M, Hollestelle A, Jager A, Huijts PE, Berns EM, Sieuwerts AM, Meijer-van Gelder ME, Collée JM, Devilee P, Hooning MJ, Martens JW, Seynaeve C.

Br J Cancer. 2014 Aug 26;111(5):1004-13. doi: 10.1038/bjc.2014.306. Epub 2014 Jun 10.

PMID:
24918820
10.

Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.

Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I; EORTC GCG and EORTC GCG Translational Research Group.

Int J Gynecol Cancer. 2014 Mar;24(3):468-77. doi: 10.1097/IGC.0000000000000089.

PMID:
24557434
11.

Supramolecular Nanofibers of Peptide Amphiphiles for Medicine.

Webber MJ, Berns EJ, Stupp SI.

Isr J Chem. 2013 Aug 1;53(8):530-554.

12.

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.

Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, Linn SC.

Breast Cancer Res. 2014 Jan 27;16(1):R13. doi: 10.1186/bcr3606.

13.

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.

Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, Linn SC.

Breast Cancer Res. 2014 Jan 21;16(1):R6. doi: 10.1186/bcr3598.

14.

MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue.

Sapino A, Roepman P, Linn SC, Snel MH, Delahaye LJ, van den Akker J, Glas AM, Simon IM, Barth N, de Snoo FA, van 't Veer LJ, Molinaro L, Berns EM, Wesseling J, Riley LB, Anderson D, Nguyen B, Cox CE.

J Mol Diagn. 2014 Mar;16(2):190-7. doi: 10.1016/j.jmoldx.2013.10.008. Epub 2013 Dec 28.

15.

CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.

Dezentjé VO, Gelderblom H, Van Schaik RH, Vletter-Bogaartz JM, Van der Straaten T, Wessels JA, Kranenbarg EM, Berns EM, Seynaeve C, Putter H, Van de Velde CJ, Nortier JW, Guchelaar HJ.

Breast Cancer Res Treat. 2014 Jan;143(1):171-9. doi: 10.1007/s10549-013-2777-6. Epub 2013 Nov 22.

PMID:
24265036
16.

Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer.

Jansen MP, Knijnenburg T, Reijm EA, Simon I, Kerkhoven R, Droog M, Velds A, van Laere S, Dirix L, Alexi X, Foekens JA, Wessels L, Linn SC, Berns EM, Zwart W.

Cancer Res. 2013 Nov 15;73(22):6632-41. doi: 10.1158/0008-5472.CAN-13-0704.

17.

Aligned neurite outgrowth and directed cell migration in self-assembled monodomain gels.

Berns EJ, Sur S, Pan L, Goldberger JE, Suresh S, Zhang S, Kessler JA, Stupp SI.

Biomaterials. 2014 Jan;35(1):185-95. doi: 10.1016/j.biomaterials.2013.09.077. Epub 2013 Oct 10.

18.

The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns.

Türbachova I, Schwachula T, Vasconcelos I, Mustea A, Baldinger T, Jones KA, Bujard H, Olek A, Olek K, Gellhaus K, Braicu I, Könsgen D, Fryer C, Ravot E, Hellwag A, Westerfeld N, Gruss OJ, Meissner M, Hasan MT, Weber M, Hoffmüller U, Zimmermann S, Loddenkemper C, Mahner S, Babel N, Berns E, Adams R, Zeilinger R, Baron U, Vergote I, Maughan T, Marme F, Dickhaus T, Sehouli J, Olek S.

Epigenetics. 2013 Nov;8(11):1226-35. doi: 10.4161/epi.26334. Epub 2013 Sep 26.

19.

Results of the two incidence screenings in the National Lung Screening Trial.

Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gatsonis CA, Gierada DS, Jain A, Jones GC, Mahon I, Marcus PM, Rathmell JM, Sicks J; National Lung Screening Trial Research Team.

N Engl J Med. 2013 Sep 5;369(10):920-31. doi: 10.1056/NEJMoa1208962.

20.

CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.

Dezentjé VO, van Schaik RH, Vletter-Bogaartz JM, van der Straaten T, Wessels JA, Kranenbarg EM, Berns EM, Seynaeve C, Putter H, van de Velde CJ, Nortier JW, Gelderblom H, Guchelaar HJ.

Breast Cancer Res Treat. 2013 Jul;140(2):363-73. doi: 10.1007/s10549-013-2619-6. Epub 2013 Jul 11.

PMID:
23842856
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk